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Abstract
Background: Glomus jugulare is a slowly growing, locally destructive tumor located in the skull base with difficult
surgical access. The operative approach is, complicated by the fact that lesions may be both intra and extradural
with engulfment of critical neurovascular structures. The tumor is frequently highly vascular, thus tumor resection
entails a great deal of morbidity and not infrequent mortality. At timeslarge residual tumors are left behind. To
decrease the morbidity associated with surgical resection of glomus jugulare, gamma knife surgery (GKS) was
performed as an alternative in 13 patients to evaluate its safety and efficacy.
Methods: A retrospective review of 13 residual or unresectable glomus jagulare treated with GKS between 2004
and 2008. Of these, 11 patients underwent GKS as the primary management and one case each was treated for
postoperative residual disease and postembolization. The radiosurgical dose to the tumor margin ranged between
12-15 Gy.
Results: Post- gamma knife surgery and during the follow-up period twelve patients demonstrated neurological
stability while clinical improvement was achieved in 5 patients. One case developed transient partial 7th nerve
palsy that responded to medical treatment. In all patients radiographic MRI follow-up was obtained, the tumor size
decreased in two cases and remained stable (local tumor control) in eleven patients.
Conclusions: Gamma knife surgery provids tumor control with a lowering of risk of developing a new cranial
nerve injury in early follow-up period. This procedure can be safely used as a primary management tool in patients
with glomus jugulare tumors, or in patients with recurrent tumors in this location. If long-term results with GKS are
equally effective it will emerge as a good alternative to surgical resection.
Introduction
Glomus jugulare tumors are rare, slow-growing, hypervas-
cular tumors that arise within the jugular foramen of the
temporal bone. They are included in a group of tumors
referred as paragangliomas, which occur at various sites
and include carotid body, glomus vagale, and glomus tym-
panic tumors. These tumors frequently invade the adjacent
jugular bulb, internal carotid artery and the lower cranial
nerves The occurrence is reported in a ratio of 1:1,000,000
in the fifth to sixth decade of life [1].
Glomus jugulare tumors are locally destructive lesions
located in one of the poorly accessible surgical regions of
the skull base. The operative approach is, complicated by
the fact that lesions may be both intradural and extradural
with engulfment of critical neurovascular structures. Thus,
it is not surprising that resection entails a great deal of
morbidity, and not infrequent mortality at times leaving
behind large residual tumors [2-5].
Time to diagnosis from the first symptom is range
between four and six years. Thus by the time they are
presented to a surgeon the tumors are often very large
and are unlikely to be resected completely. Treatment is
controversial. Traditional treatment options include sur-
gery with or without preoperative embolization followed
by postoperative conventional external beam radiother-
apy. These have been associated with significant morbid-
ity and mortality [6-9].
Glomus jugulare tumors occur predominantly in
women in the fifth and sixth decades of life. Because of
the insidious onset of symptoms, these tumors often go
unnoticed, and delay in diagnosis is frequent. Because of
the location and extent of involvement, glomus jugulare
tumors present a significant diagnostic and management
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common tumor of the middle ear and are second to
vestibular schwannoma as the most common tumor of
the temporal bone [10].
The most common symptoms are conductive hearing
loss and pulsatile tinnitus. Other aural signs and symp-
toms are ear fullness, otorrhea, hemorrhage, bruit, and
the presence of a middle ear mass. Significant ear pain
is uncommon. Involvement of the inner ear produces
vertigo and sensorineural hearing loss [11].
Cranial nerve involvement produces hoarseness and
dysphagia. The presence of jugular foramen syndrome
(paresis of cranial nerves IX-XI) is pathognomonic of
this tumor, but it usually follows the initial symptoms of
hearing loss and pulsatile tinnitus. Less commonly, glo-
mus tumors produce facial nerve palsy, hypoglossal
nerve palsy, or horner syndrome. Ataxia and brain stem
symptoms may also develop. Involvement of the dural
sinuses may mimic sinus thrombosis [11,12].
In about 2-4% of cases, the first or leading symptoms
are hypertension and tachycardia (pheochromocytoma
like symptoms) produced by catecholamines, norepi-
nephrine, or dopamine excreted by the tumor. Also,
somatostatin, vasoactive intestinal polypeptide, calcito-
nin, and neuron-specific enolase may be produced by
the tumor. Other related symptoms include headache,
perspiration, pallor, and nausea [13,14].
The treatment of glomus jugulare tumors presents the
surgeon with a significant management problem.
Because the neoplasm originates in the region of the
jugular bulb, it frequently involves the lower cranial
nerves, with occasional extension into the posterior
fossa. Despite extensive work on the development of
surgical and radiation treatment strategies, considerable
controversy still exists regarding the optimal manage-
ment of these lesions. Despite these therapies, tumor
control can be difficult to achieve particularly without
undue risk of patient morbidity or mortality [15].
Microsurgical removal of glomus jugulare tumors is
frequently associated with injury of the lower cranial
nerves. To decrease the morbidity associated with tumor
management, gamma knife surgery (GKS) has been per-
formed as an alternative to resection [16].
Traditionally, conventional fractionated external beam
radiotherapy was used to treat residual tumors with
varying degrees of success ranging from a maximum of
61-71% to an average of 23%. Side-effects include
osteoradionecrosis of the temporal bone, radiation
necrosis of the temporal lobe, mastoiditis and second
malignancies [10]. Although the glomus cells per se are
radioresistant and radiotherapy helps to halt tumor
growth by inducing fibrosis around the supplying ves-
sels. Stereotactic radiosurgery with the Gamma knife
system delivers precise high-dose radiation to a small
localized field to increase the chances of obliterative
endarteritis while reducing complications by sparing
adjacent normal structures [7,17].
Materials and methods
Objective
To evaluate the safety and efficacy of gamma knife surgery
(GKS) for controlling the glomus jugulare tumors
Method
Between 2004 and 2008, 13 cases with glomus jagulare
tumors were treated using gamma knife surgery at the
International Medical Center, Cairo, Egypt. The follow-
up period ranged from 12 to 48 months. All patients
underwent a complete neurological assessment before
the treatment that included MRI and audiograms.
Follow-up included clinical neurological evaluation and
MRI brain that were done regularly at 6 monthly inter-
vals in the first year and yearly afterward.
Radiosurgery technique
The Elekta Leksell® gamma knife was used for the treat-
ment. Target localization was achieved using MRI per-
formed with T1 axial and coronal-weighted sequence at
2 mm slice thickness with and without contrast, T1- fat
saturation sequence and also T2 axial sequence was
used to eliminate tumor edema. Treatment planning
was performed with Elekta Leksell® Gamma Plan. Treat-
ment peripheral dose ranged between 12-15 Gy usually
at 35% to 50% isodose curve. The maximum dose to the
adjacent brain stem area ranged between 10 - 12 Gy.
Results
Eleven patients underwent gamma knife surgery as pri-
mary treatment, one had partial microsurgical tumor
removal and one had underwent tumor embolization
pre-gamma knife surgery.
The mean age of patients was 43.6 years (range, 22-64
years). There were 11 females and two male. The
tumors were located at left side in 10 cases and right
side in 3 cases (Figure 1). The most common neurologi-
cal deficit was IX, X, XI cranial nerve paresis in
7 patients, sensorineural deterioration in hearing, facial
paresis, XII cranial nerve paresis and trigeminal impair-
ment were also recorded. Pulstile tinnitus was recorded
in 9 cases and ataxia in 3 cases.
Of the 13 tumors that underwent GKS, the mean
tumor volume was 8.4 cc (range 2.6-19.4 cc). The tumor
peripheral dose was 15 Gy in all cases at mean isodose
curve of 37.7% (range 35 to 50%), (Figure 2).
The clinical follow-up period ranged between 12 to
48 months. All patients had follow up clinically and by
MRI at 6 monthly interval in the first year and yearly
afterward.
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during the follow-up period (starting in 6 months to 24
months post gamma knife surgery). Improvement was
mainly in dysphonia, regurgitation and also shoulder
pain. Seven cases showed stable clinical disease with no
additional symptoms or signs.
One patient developed transient partial 7th nerve palsy
at 9 months post gamma knife surgery.
Magnetic resonance imaging follow-up was available
for all the 13 patients. Eleven patients showed local
tumor control and two patients showed decrease in
tumor size (Figure 3).
Discussion
Glomus jagulare tumors though radioresistant, radiation
has been found to be helpful in controlling tumor
growth by inducing fibrosis around the supplying vessels
[7,11,13].
In a study by Pollock (2004) GKS was used as the pri-
mary management in 19 patients and for recurrent
glomus jugulare tumors for 23 patients.Of these,
12 tumors (31%) decreased in size, 26 (67%) remained
unchanged, and one (2%) grew. The patient whose
tumor grew underwent repeated GKS. Progression-free
survival after GKS was 100% at 3 and 7 years, and 75%
at 10 years. Six patients (15%) experienced new deficits
(hearing loss alone in three, facial numbness and hear-
ing loss in one, vocal cord paralysis and hearing loss in
one, and temporary imbalance and/or vertigo in one). In
26 patients in whom hearing could be tested before
GKS, hearing preservation was achieved in 86% and 81%
at 1 and 4 years post treatment, respectively [14].
Ganj and Abdelkarim [8] reported on 14 patients with
glomus jagulare tumorstreated with mean dose of
13.6 Gy (range 12-16) with mean follow-up period of
28 months (range 6 to 60 months). All the tumors
except one were Fisch type D and the mean volume was
Figure 1 Stereotactic MRI + contrast pre-gamma knife surgery
for glomus jugulare tumor extends to the atlas vertebrae level.
Figure 2 Gamma plan for the same case of the glomus jugulare treated with 15 Gy to the margin at 35% isodose curve.
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3, (range 3.7-28.4 cm
3). Volume of eight lesions
became smaller while 6 remain unchanged. Two
patients with bruit had no improvement in their symp-
toms. Among the other 12, 5 had symptomatic improve-
ment of dysphagia, 4 in dysphonia, 3 in facial numbness
and 3 in ataxia [8].
In our study, 5 patients showed improvement in their
neurological symptoms and seven cases had stable clini-
cal disease. Radiologically Eleven patients showed local
tumor control in the follow-up MRI and two patients
showed decrease in tumor size. Clincial improvement
was seen irrespective of the tumor response.
Stereotactic radiosurgery with the Gamma knife sys-
tem delivers precise high-dose radiation to a small loca-
lized field to increase the chances of obliterative
endarteritis while reducing complications by sparing
adjacent normal structures. With the present results the
GKS appears to be a viable alternative for large, residual
or recurrent glomus juglare tumors. Longer follow-up
periods are required to assess long-term effects in a
benign disease, tumor control and quality of life indices
would appear to be more significant than eradication
[11,12].
Conclusion
Gamma Knife Surgery is a safe and effective treatment
for glomus jugulare tumors, particularly in patients with
preserved glossopharyngeal and vagus nerve function,
after surgical recurrence, in the elderly, and in patients
with serious preexisting medical conditions.
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